Skip to main content
SpringerLink
Log in

Standards in der Therapie des Ovarialkarzinoms

Standards in the treatment of ovarian cancer

  • Zum Thema
  • Published:
Der Gynäkologe Aims and scope

Zusammenfassung

Das Ovarialkarzinom ist der gynäkologische Tumor mit der höchsten Mortalität. In letzter Zeit hat es zahlreiche neue Erkenntnisse über den Stellenwert und Umfang der operativen Therapie dieser Erkrankung gegeben. Die Neuerungen bei der Chemotherapie der Primärerkrankung und des Rezidives sind ebenfalls zahlreich. Die Umsetzung dieser in nationalen und internationalen Standards und Leitlinien implementierten neuen Entwicklungen in den klinischen Alltag ist zur Verbesserung der Situation der Betroffenen dringend erforderlich.

Abstract

Epithelial ovarian cancer is the gynecological tumor with the highest mortality rate. Recently, numerous new findings have emerged about status and extent of surgical therapy of this disease. Innovations regarding chemotherapy of primary and recurrent disease are also numerous. It is essential for the improvement of the patients’ situation to transfer these new developments already implemented in national and international standards and guidelines to clinical practice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2

Literatur

  1. Bristow RE, Tomacruz RS, Armstrong DK et al. (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20:1248–1259

    Article  PubMed  Google Scholar 

  2. Colombo N, Guthrie D, Chiari S et al. (2003) International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer. J Natl Cancer Inst 95:125–132

    PubMed  Google Scholar 

  3. du Bois A, Lück HJ, Bauknecht T et al. (2000) 2nd-line-Chemotherapie nach Platin- oder Platin-Paclitaxel-haltiger Primärtherapie beim Ovarialkarzinom: eine systematische Übersicht der publizierten Daten bis 1998. Geburtsh Frauenheilk 60:41–58

    Article  Google Scholar 

  4. du Bois A, Lück HJ, Meier W et al. (2003) A randomized clinical trial of Cisplatin/Paclitaxel versus Carboplatin/Paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95:1320–1329

    PubMed  Google Scholar 

  5. du Bois A, Pfisterer J, Kellermann L (2001) Die Therapie des fortgeschrittenen Ovarialkarzinoms in Deutschland. Gynäkologe 34:1029–1040

    Google Scholar 

  6. Markman M, Hoskins W (1992) Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population. J Clin Oncol 10:513–514

    CAS  PubMed  Google Scholar 

  7. McGuire WP, Hoskins WJ, Brady MF et al. (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and Stage IV ovarian cancer. New Engl J Med 334:1–6

    Article  CAS  PubMed  Google Scholar 

  8. Muggia FM, Braly PS, Brady MF et al. (2000) Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 18:106–115

    CAS  PubMed  Google Scholar 

  9. Ozols RF, Bundy BN, Greer BE et al. (2003) Phase III Trial of Carboplatin and Paclitaxel compared with Cisplatin and Paclitaxel in patients with optimally resected stage III Ovarian cancer. A Gynecologic Oncology Group Study. J Clin Oncol 21:3194–3200

    Article  PubMed  Google Scholar 

  10. Pfisterer J, Plante M, Vergote I et al. (2004) Gemcitabine/Carboplatin (GC) vs. Carboplatin (C) in Platinum Sensitive Recurrent Ovarian Cancer (OVCA). Results of a Gynecologic Cancer Intergroup Randomized Phase III Trial of the AGO OVAR, the NCIC CTG and the EORTC GCG. Proc Am Soc Clin Oncol:Nr. 5005

    Google Scholar 

  11. Piccart MJ, Bertelsen K, James K et al. (2000) Randomized Intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced ovarian cancer. J Natl Cancer Inst 92:699–708

    Article  CAS  PubMed  Google Scholar 

  12. Sakurai S, Shimizu Y, Utsugi K et al. (2002) Validity of complete paraaortic and pelvic lymphadenectomy in apparent stage I (pT1) ovarian carcinoma. Proc Am Soc Clin Oncol:Nr. 801

    Google Scholar 

  13. The ICON and AGO Collaborators (2003) Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/ AGO-OVAR-2.2 trial. Lancet 361:2099–2106

    Article  PubMed  Google Scholar 

  14. The International Collaborative Ovarian Neoplasm (ICON) Group (2002) Paclitaxel plus carboplatin versus standard chemotherapy with either single agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 360:505–515

    Article  PubMed  Google Scholar 

  15. Trimbos JB (2000) Staging of early ovarian cancer and the impact of lymph node sampling. Int J Gynecol Cancer 10 (S1):8–11

    Article  PubMed  Google Scholar 

  16. Trimbos JB, Vergote I, Bolis G et al. (2003) Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. J Natl Cancer Inst 95:113–125

    Article  CAS  PubMed  Google Scholar 

Download references

Interessenkonflikt:

Der korrespondierende Autor versichert, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt ist, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen.

Author information

Authors and Affiliations

  1. Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum Schleswig-Holstein, Campus Kiel

    J. Pfisterer

  2. Klinik für Gynäkologie und Gynäkologische Onkologie, Dr. Horst Schmidt Kliniken Wiesbaden

    A. du Bois

  3. Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Michaelisstraße 16, 24105 , Kiel

    J. Pfisterer

Authors
  1. J. Pfisterer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. du Bois
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. Pfisterer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pfisterer, J., du Bois, A. Standards in der Therapie des Ovarialkarzinoms. Gynäkologe 37, 662–668 (2004). https://doi.org/10.1007/s00129-004-1561-4

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00129-004-1561-4

Schlüsselwörter

Keywords

Search

Navigation